132 related articles for article (PubMed ID: 26727592)
1. Preclinical Evaluation of Liposomal C8 Ceramide as a Potent anti-Hepatocellular Carcinoma Agent.
Lv H; Zhang Z; Wu X; Wang Y; Li C; Gong W; Gui L; Wang X
PLoS One; 2016; 11(1):e0145195. PubMed ID: 26727592
[TBL] [Abstract][Full Text] [Related]
2. The anti-hepatocellular carcinoma cell activity by a novel mTOR kinase inhibitor CZ415.
Zhang W; Chen B; Zhang Y; Li K; Hao K; Jiang L; Wang Y; Mou X; Xu X; Wang Z
Biochem Biophys Res Commun; 2017 Jun; 487(3):494-499. PubMed ID: 28366631
[TBL] [Abstract][Full Text] [Related]
3. C6 ceramide sensitizes the anti-hepatocellular carcinoma (HCC) activity by AZD-8055, a novel mTORC1/2 dual inhibitor.
Liu M; Gu P; Guo W; Fan X
Tumour Biol; 2016 Aug; 37(8):11039-48. PubMed ID: 26897748
[TBL] [Abstract][Full Text] [Related]
4. KU-0060648 inhibits hepatocellular carcinoma cells through DNA-PKcs-dependent and DNA-PKcs-independent mechanisms.
Chen MB; Zhou ZT; Yang L; Wei MX; Tang M; Ruan TY; Xu JY; Zhou XZ; Chen G; Lu PH
Oncotarget; 2016 Mar; 7(13):17047-59. PubMed ID: 26933997
[TBL] [Abstract][Full Text] [Related]
5. Identification of sphingosine kinase 1 (SphK1) as a primary target of icaritin in hepatocellular carcinoma cells.
Lu PH; Chen MB; Liu YY; Wu MH; Li WT; Wei MX; Liu CY; Qin SK
Oncotarget; 2017 Apr; 8(14):22800-22810. PubMed ID: 28206952
[TBL] [Abstract][Full Text] [Related]
6. CC-223 blocks mTORC1/C2 activation and inhibits human hepatocellular carcinoma cells in vitro and in vivo.
Xie Z; Wang J; Liu M; Chen D; Qiu C; Sun K
PLoS One; 2017; 12(3):e0173252. PubMed ID: 28334043
[TBL] [Abstract][Full Text] [Related]
7. 4SC-202 activates ASK1-dependent mitochondrial apoptosis pathway to inhibit hepatocellular carcinoma cells.
Fu M; Wan F; Li Z; Zhang F
Biochem Biophys Res Commun; 2016 Mar; 471(2):267-73. PubMed ID: 26773495
[TBL] [Abstract][Full Text] [Related]
8. MEK-ERK inhibition potentiates WAY-600-induced anti-cancer efficiency in preclinical hepatocellular carcinoma (HCC) models.
Wang K; Fan Y; Chen G; Wang Z; Kong D; Zhang P
Biochem Biophys Res Commun; 2016 May; 474(2):330-337. PubMed ID: 27107695
[TBL] [Abstract][Full Text] [Related]
9. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo.
Shao H; Gao C; Tang H; Zhang H; Roberts LR; Hylander BL; Repasky EA; Ma WW; Qiu J; Adjei AA; Dy GK; Yu C
J Hepatol; 2012 Jan; 56(1):176-83. PubMed ID: 21835141
[TBL] [Abstract][Full Text] [Related]
10. Identification of mTOR as a primary resistance factor of the IAP antagonist AT406 in hepatocellular carcinoma cells.
Zhen MC; Wang FQ; Wu SF; Zhao YL; Liu PG; Yin ZY
Oncotarget; 2017 Feb; 8(6):9466-9475. PubMed ID: 28036295
[TBL] [Abstract][Full Text] [Related]
11. Hispidulin inhibits hepatocellular carcinoma growth and metastasis through AMPK and ERK signaling mediated activation of PPARγ.
Han M; Gao H; Ju P; Gao MQ; Yuan YP; Chen XH; Liu KL; Han YT; Han ZW
Biomed Pharmacother; 2018 Jul; 103():272-283. PubMed ID: 29656183
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis signal-regulating kinase 1 mediates the inhibitory effect of hepatocyte nuclear factor-4α on hepatocellular carcinoma.
Jiang CF; Wen LZ; Yin C; Xu WP; Shi B; Zhang X; Xie WF
Oncotarget; 2016 May; 7(19):27408-21. PubMed ID: 27050273
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of eukaryotic initiation factor 4E phosphorylation by cercosporamide selectively suppresses angiogenesis, growth and survival of human hepatocellular carcinoma.
Liu Y; Sun L; Su X; Guo S
Biomed Pharmacother; 2016 Dec; 84():237-243. PubMed ID: 27662474
[TBL] [Abstract][Full Text] [Related]
14. Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis.
Huynh H; Nguyen TT; Chow KH; Tan PH; Soo KC; Tran E
BMC Gastroenterol; 2003 Aug; 3():19. PubMed ID: 12906713
[TBL] [Abstract][Full Text] [Related]
15. The activation of p38 and JNK by ROS, contribute to OLO-2-mediated intrinsic apoptosis in human hepatocellular carcinoma cells.
Zhang Z; Zhang C; Ding Y; Zhao Q; Yang L; Ling J; Liu L; Ji H; Zhang Y
Food Chem Toxicol; 2014 Jan; 63():38-47. PubMed ID: 24211866
[TBL] [Abstract][Full Text] [Related]
16. Lanatoside C, a cardiac glycoside, acts through protein kinase Cδ to cause apoptosis of human hepatocellular carcinoma cells.
Chao MW; Chen TH; Huang HL; Chang YW; HuangFu WC; Lee YC; Teng CM; Pan SL
Sci Rep; 2017 Apr; 7():46134. PubMed ID: 28387249
[TBL] [Abstract][Full Text] [Related]
17. FTY720 induces apoptosis in hepatocellular carcinoma cells through activation of protein kinase C delta signaling.
Hung JH; Lu YS; Wang YC; Ma YH; Wang DS; Kulp SK; Muthusamy N; Byrd JC; Cheng AL; Chen CS
Cancer Res; 2008 Feb; 68(4):1204-12. PubMed ID: 18281497
[TBL] [Abstract][Full Text] [Related]
18. Pre-clinical assessment of A-674563 as an anti-melanoma agent.
Zou Y; Fan G; Wang X
Biochem Biophys Res Commun; 2016 Aug; 477(1):1-8. PubMed ID: 26970307
[TBL] [Abstract][Full Text] [Related]
19. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
[TBL] [Abstract][Full Text] [Related]
20. Sauchinone exerts anticancer effects by targeting AMPK signaling in hepatocellular carcinoma cells.
Kim YW; Jang EJ; Kim CH; Lee JH
Chem Biol Interact; 2017 Jan; 261():108-117. PubMed ID: 27871897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
